Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

12.69

+0.51

(+4.23%)

As of 09:53AM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	12.18
Open	12.32
Bid	12.30 x 1300
Ask	12.34 x 1800
Day's Range	12.24 - 12.72
52 Week Range	6.18 - 27.96
Volume	192,935
Avg. Volume	5,176,811

Market Cap	2.003B
Beta (5Y Monthly)	0.47
PE Ratio (TTM)	N/A
EPS (TTM)	-2.30
Earnings Date	Nov 02, 2022 - Nov 07, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	27.23

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IOVA

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Iovance Biotherapeutics, Inc.
Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Rating
Fair Value
Economic Moat
2 days agoMorningstar

All

Zacks
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track
Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
GlobeNewswire
Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates
First Biologics License Application (BLA) Submission on Track in August 2022 SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported second quarter and first half 2022 financial results and corporate updates. Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive O
- Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022
  GlobeNewswire
- 1-800-FLOWERS.COM, Inc. to Release Results for its Fiscal 2022 Fourth Quarter and Full Year on Thursday, September 1, 2022
  Business Wire
GlobeNewswire
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022
SAN CARLOS, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter financial results on Thursday, August 4, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To participate in the conference call, please register at https://register.vevent.com/register/BI2